On April 26, 2025, CG Oncology, Inc. announced promising results from their clinical trial, showing a 75.5% complete response rate for their drug cretostimogene in treating high-risk bladder cancer patients, with a median response duration of 28 months and a 97.3% rate of patients free from disease progression at 24 months.